Capricor Therapeutics (CAPR) EBIT (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly EBIT of -$36.8 million for Q1 2026, down 47.19% year-over-year from -$69.6 million in Q1 2025, and down 26.12% quarter-over-quarter from -$29.2 million in Q4 2025.
Capricor Therapeutics (CAPR) EBIT (2010 - 2026) Analysis & Trends
Capricor Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$36.8 million for Q1 2026.
- In Q1 2026, EBIT fell 47.19% year-over-year to -$36.8 million; the TTM figure through Mar 2026 stood at -$119.9 million (down 109.38% YoY), while the FY2025 annual figure was -$108.1 million, down 154.07% from the prior year.
- EBIT for Q1 2026 stood at -$36.8 million, down from -$29.2 million in the prior quarter.
- The five-year high for EBIT was -$1.3 million in Q4 2023, with the low at -$36.8 million in Q1 2026.
- The 5-year median for EBIT is -$8.2 million (2023), against an average of -$14.2 million.
- The sharpest annual moves came in 2023 and 2024: EBIT surged 84.12% in 2023, then plunged 500.66% in 2024.
- Capricor Therapeutics' EBIT stood at -$8.1 million in 2022, then soared by 84.12% to -$1.3 million in 2023, then slumped by 500.66% to -$7.7 million in 2024, then tumbled by 278.83% to -$29.2 million in 2025, then dropped by 26.12% to -$36.8 million in 2026.
- Business Quant data shows CAPR's EBIT at -$36.8 million in Q1 2026, -$29.2 million in Q4 2025, and -$26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -36.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.77 Mn |
| Dec 31, 2025 | -29.16 Mn |
| Sep 30, 2025 | -26.28 Mn |
| Jun 30, 2025 | -27.72 Mn |
| Mar 31, 2025 | -24.98 Mn |
| Dec 31, 2024 | -7.70 Mn |
| Sep 30, 2024 | -13.01 Mn |
| Jun 30, 2024 | -11.59 Mn |
| Mar 31, 2024 | -10.27 Mn |
| Dec 31, 2023 | -1.28 Mn |
| Sep 30, 2023 | -6.86 Mn |
| Jun 30, 2023 | -7.75 Mn |
| Mar 31, 2023 | -8.18 Mn |
| Dec 31, 2022 | -8.07 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -7.32 Mn |
| Mar 31, 2022 | -7.83 Mn |
| Dec 31, 2021 | -6.38 Mn |
| Sep 30, 2021 | -4.31 Mn |
| Jun 30, 2021 | -5.08 Mn |